Wednesday, June 18, 2025 8:52:41 AM
Shenzhen CICD used to show a picture of the assembled electronic device. They don't show the picture any more but the actual device arrives in the USA as a sealed device with battery and wire loop.
Kelly doesn't solder or seal or assembled anything. Somebody in the USA drops the fully assembled device in a box with some literature. KT Tape too -- nobody at KT Tape assembles anything plastic or electronic. The Chinese manufacturer puts the KT logo, or the RecoveryRx logo, on the device, and anyone else wanting to do that can have their own logo put on the device and sell it, since the patents are gone.
Kelly doesn't "clearly write" anything. Read her quote again. She is vague and obtuse as usual. She says that "enough of the COGS" is done in the USA to say "MADE in the USA" but what does that mean? They probably pay the Chinese manufacturer $10 per unit or close to that, so the spend another
$11 dropping that assembled device into a box? BS, I say, and the FTC apparently agrees with me because someone complained to the FTC and now "MADE in the USA" is gone from the website.
CTXR is tricky. The recent dilution was done at $1.00 so I think this selling under $1.00 is overdone. I've been buying because I already have enough CTOR and that price isn't coming back to earth, even though the company just said, in typical Safe Harbor Positive Spin wording, that product launch is not going to happen in the first half of 2025 as previously forecast.
Recent CTXR News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 01:03:55 PM
- Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers • PR Newswire (US) • 03/10/2026 12:47:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 02:25:21 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 02/24/2026 01:04:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/24/2026 01:02:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/24/2026 01:00:41 PM
- Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program • PR Newswire (US) • 02/24/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 01:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2026 01:00:57 PM
- Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ • PR Newswire (US) • 02/13/2026 01:00:00 PM
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ • PR Newswire (US) • 02/13/2026 01:00:00 PM
- Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar • PR Newswire (US) • 02/11/2026 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/28/2026 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 09:49:06 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update • PR Newswire (US) • 12/23/2025 09:30:00 PM
- Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update • PR Newswire (US) • 12/23/2025 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/23/2025 09:21:08 PM
- Citius Oncology Shares Sink After Announcing $18M Fundraising Deal • IH Market News • 12/09/2025 03:19:37 PM
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 12/09/2025 01:30:00 PM
- Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim • PR Newswire (US) • 12/04/2025 01:37:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 10:03:08 PM
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) • PR Newswire (US) • 12/01/2025 05:00:00 PM
- Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration • PR Newswire (US) • 11/21/2025 01:37:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
